[go: up one dir, main page]

RU2019118791A - Популяции клеток почек и их применение - Google Patents

Популяции клеток почек и их применение Download PDF

Info

Publication number
RU2019118791A
RU2019118791A RU2019118791A RU2019118791A RU2019118791A RU 2019118791 A RU2019118791 A RU 2019118791A RU 2019118791 A RU2019118791 A RU 2019118791A RU 2019118791 A RU2019118791 A RU 2019118791A RU 2019118791 A RU2019118791 A RU 2019118791A
Authority
RU
Russia
Prior art keywords
cell population
population
cells
express
enriched
Prior art date
Application number
RU2019118791A
Other languages
English (en)
Other versions
RU2805243C2 (ru
Inventor
Джойдип БАСУ
Келли И. ГАТРИ
Доминик М. ЮСТЕВИЧ
Тереза Б. БЕРНЕТТ
Эндрю БРЮС
Рассел В. КЕЛЛИ
Джон В. ЛУДЛОУ
Original Assignee
инРиджен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by инРиджен filed Critical инРиджен
Publication of RU2019118791A publication Critical patent/RU2019118791A/ru
Application granted granted Critical
Publication of RU2805243C2 publication Critical patent/RU2805243C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741Keratin; Cytokeratin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081Purging biological preparations of unwanted cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/104Aminoacyltransferases (2.3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y203/00Acyltransferases (2.3)
    • C12Y203/02Aminoacyltransferases (2.3.2)
    • C12Y203/02002Gamma-glutamyltransferase (2.3.2.2)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/02Atmosphere, e.g. low oxygen conditions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/58Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/599Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4742Keratin; Cytokeratin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/91045Acyltransferases (2.3)
    • G01N2333/91074Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)

Claims (13)

1. Обогащенная гетерогенная популяция клеток почек млекопитающих, полученная из образца почки млекопитающего,
где указанная обогащенная популяция содержит клетки, которые экспрессируют VEGF и KIM-1 до детектируемых уровней в культуральной среде,
где более 4,5% клеток в указанной обогащенной популяции экспрессируют GGT-1, и
где более 80% клеток в указанной обогащенной популяции экспрессируют цитокератин.
2. Популяция клеток по п. 1, где VEGF, KIM-1, GGT-1 и цитокератин являются детектируемыми с помощью моноклонального или поликлонального антитела.
3. Популяция клеток по п. 1, где более 18% клеток экспрессируют GGT-1.
4. Популяция клеток по п. 1, где цитокератин выбирают из CK8, CK18, CK19 и их комбинаций.
5. Популяция клеток по п. 4, где более 80% экспрессируют CK18.
6. Популяция клеток по п. 1, где цитокератин является детектируемым с помощью поликлонального антитела.
7. Популяция клеток по п. 1, дополнительно отличающаяся экспрессией AQP клетками в указанной обогащенной популяции.
8. Популяция клеток по п. 1, дополнительно отличающаяся тем, что менее 40% клеток в указанной обогащенной популяции экспрессируют AQP2.
9. Популяция клеток по п. 7, где AQP2 является детектируемым с помощью моноклонального антитела.
10. Популяция клеток по п. 1, где указанный образец почки млекопитающего представляет собой образец почки человека.
RU2019118791A 2012-10-24 2013-10-24 Популяции клеток почек и их применение RU2805243C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261718150P 2012-10-24 2012-10-24
US61/718,150 2012-10-24
US201361876616P 2013-09-11 2013-09-11
US61/876,616 2013-09-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015119514A Division RU2702721C2 (ru) 2012-10-24 2013-10-24 Популяции клеток почек и их применение

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2023125277A Division RU2023125277A (ru) 2012-10-24 2023-10-03 Популяции клеток почек и их применение

Publications (2)

Publication Number Publication Date
RU2019118791A true RU2019118791A (ru) 2019-07-11
RU2805243C2 RU2805243C2 (ru) 2023-10-12

Family

ID=

Also Published As

Publication number Publication date
KR102160725B1 (ko) 2020-09-29
AU2022201010B2 (en) 2024-11-14
WO2014066699A1 (en) 2014-05-01
RU2015119514A (ru) 2016-12-20
CA2889270C (en) 2024-09-10
EP3901251B9 (en) 2025-06-18
DK3901251T3 (da) 2025-03-03
EP3567099A1 (en) 2019-11-13
FI3901251T3 (fi) 2025-03-21
AU2013334276A1 (en) 2015-05-14
ES2876177T3 (es) 2021-11-12
BR122020018576B1 (pt) 2022-07-05
JP2016504017A (ja) 2016-02-12
AU2013334276B2 (en) 2019-07-04
AU2022201010A1 (en) 2022-03-03
KR102674303B1 (ko) 2024-06-12
EP2912165A1 (en) 2015-09-02
NZ741724A (en) 2020-02-28
KR20210018965A (ko) 2021-02-18
HUE046176T2 (hu) 2020-02-28
US12409191B2 (en) 2025-09-09
KR102460536B1 (ko) 2022-10-31
EP4527921A3 (en) 2025-05-21
BR112015009042B1 (pt) 2021-10-19
KR20150085818A (ko) 2015-07-24
SI2912165T1 (sl) 2019-11-29
JP2019141067A (ja) 2019-08-29
EP3901251A1 (en) 2021-10-27
US10363274B2 (en) 2019-07-30
PL3567099T3 (pl) 2021-11-29
EP3901251B1 (en) 2024-12-25
CN104937095A (zh) 2015-09-23
HK1215448A1 (en) 2016-08-26
AU2019204178B2 (en) 2021-11-18
AU2019204178A1 (en) 2019-07-04
AU2025200927A1 (en) 2025-03-06
US20220347221A1 (en) 2022-11-03
ES3014420T3 (en) 2025-04-22
US20250152632A1 (en) 2025-05-15
BR112015009042A8 (pt) 2017-10-10
CA3240629A1 (en) 2014-05-01
KR20200113287A (ko) 2020-10-06
EP2912165B1 (en) 2019-06-19
KR20220150419A (ko) 2022-11-10
DK3567099T3 (da) 2021-06-07
NZ707873A (en) 2019-01-25
BR112015009042A2 (pt) 2017-07-04
RU2702721C2 (ru) 2019-10-09
JP6696023B2 (ja) 2020-05-20
CN110184232A (zh) 2019-08-30
CN117660296A (zh) 2024-03-08
EP3567099B1 (en) 2021-04-21
JP6509119B2 (ja) 2019-05-08
US20170281684A1 (en) 2017-10-05
US11369639B2 (en) 2022-06-28
CA2889270A1 (en) 2014-05-01
ES2744979T3 (es) 2020-02-27
CN104937095B (zh) 2019-06-07
PT2912165T (pt) 2019-09-26
EP4527921A2 (en) 2025-03-26
KR102215476B1 (ko) 2021-02-17
DK2912165T3 (da) 2019-09-16
KR20240096798A (ko) 2024-06-26
US20200101112A1 (en) 2020-04-02
US20150246073A1 (en) 2015-09-03
HUE054882T2 (hu) 2021-10-28
ES2744979T8 (es) 2020-04-28
CN110184232B (zh) 2023-10-20
PL2912165T3 (pl) 2020-01-31

Similar Documents

Publication Publication Date Title
De Boeck et al. Improving the energy performance of residential buildings: A literature review
Freedman et al. The (dys) functional extracellular matrix
HUS1700049I1 (hu) Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
EA201201016A1 (ru) Антидоты антикоагулянтов
BR112015019341A2 (pt) Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
EA201690465A1 (ru) Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
CR20150437A (es) Construcciones de anticuerpos para cdh19 y cd3
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
CL2008002085A1 (es) Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
BR112015028457A8 (pt) Composições cosméticas compreendendo óleo de microalgas
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
DK201100401A (da) Glideleje
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы
BR112015019343A2 (pt) Anticorpo anti-her2, composição, método para produção de uma população de anticorpos, células epiteliais das glândulas mamárias, e, mamífero não humano transgênico
BR112012033163A2 (pt) ''anticorpos monoclonais, linhagens celulares, usos de um anticorpo, kit, métodos para detectar um anticorpo, composição de anticorpo e uso de uma composição de anticorpo''
EA201301090A1 (ru) Антидоты антикоагулянтов
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
BR112015031623A2 (pt) grânulos com núcleos lisos pequenos
BR112012033727A2 (pt) células semelhantes a tr1 de produção de il-13 e uso das mesmas
RU2019118791A (ru) Популяции клеток почек и их применение
WO2013150375A3 (en) Endothelial cells activation biomarkers characterizing antibody mediated rejection and uses thereof
RU2013107144A (ru) Способ прогнозирования самопроизвольного выкидыша